Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BHMT | Q93088 | 3/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106831 | 0.85 | — | — | |
| SCHEMBL788769 | 0.84 | KMT2A (0.53) | TDP1KMT2ALMNAHSD17B10BHMT | |
| SCHEMBL11938132 | 0.82 | KMT2A (0.50) | TDP1KMT2ALMNAHSD17B10BHMT | |
| SCHEMBL3068716 | 0.82 | TSHR (0.44) | TDP1KMT2ALMNAHSD17B10BHMT | |
| SCHEMBL11862251 | 0.79 | FAAH (0.45) | TDP1KMT2ALMNAHSD17B10BLM | |
| SCHEMBL3913691 | 0.78 | LMNA (0.70) | TDP1KMT2ALMNAHSD17B10BHMT | |
| SCHEMBL19838190 | 0.77 | BHMT (0.61) | TDP1KMT2ALMNAHSD17B10BHMT | |
| SCHEMBL22257519 | 0.77 | KMT2A (0.37) | TDP1KMT2ALMNAHSD17B10BHMT | |
| SCHEMBL10339731 | 0.77 | CES2 (0.50) | KMT2AHSD17B10BLMALDH1A1KDM4E | |
| SCHEMBL80649 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-7408023-B2 | Peptoids incorporating chemoselective functionalities | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20060188916-A1 | Peptoids incorporating chemoselective functionalities | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2006-08-24 | — | — | US | disclosed |
| US-7030216-B2 | Peptoids incorporating chemoselective functionalities | CHIRON CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| US-20020169281-A1 | Peptoids incorporating chemoselective functionalities | CHIRON CORPORATION | 2002-11-14 | — | — | US | disclosed |
| WO-2002081637-A2 | PEPTIDES INCORPORATING CHEMOSELECTIVE FUNCTIONALITIES | CHIRON CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060188916-A1 | Peptoids incorporating chemoselective functionalities | VIP, PCNA, DNPEP | TDP1 3053/4885KMT2A 3998/4885LMNA 3642/4885 |
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | TAP1, TIMCC, CD81 | TDP1 4227/4885KMT2A 2917/4885LMNA 4501/4885 |
| US-20020169281-A1 | Peptoids incorporating chemoselective functionalities | VIP, PCNA, DNPEP | TDP1 3053/4885KMT2A 3998/4885LMNA 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.